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Summary
The development of technology has enabled fast and easy determination of tumor markers and hormones at all levels 
of medical and biochemical diagnostics. Markers and hormones are most commonly determined by immunoassays and 
methods of molecular diagnostics. Immunoassays are based on the specifi c antibody-antigen reaction. Numerous factors 
during analysis may aﬀ ect the measurement of tumor markers and hormones in patient samples (1). Although immuno-
assays are sensitive and reproducible they can miss the specifi city and accuracy. Immunoassays are infl uenced by various 
interferences and most common of them will be explained in text below.
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NAJČEŠĆE INTERFERENCIJE KARAKTERISTIČNE ZA IMUNOKEMIJSKE METODE
Sažetak
Razvoj tehnologije je omogućio brzo i jednostavno određivanje hormona i markera. Najčešće se određuju imunokemij-
skim i metodama olekularne biologije. Imunokemijski testovi se temelje na specifi čnoj reakciji protutijelo-antigen. Brojni 
faktori mogu utjecati na određivanje tumorskih markera i hormona u uzorku krvi. Iako su imunokemijske metode osjetljive 
i reproducibilne može im nedostajati specifi čnosti i točnosti. Najčešće interferencije su opisane u tekstu.
KLJUČNE RIJEČI: interferencije, imuno testovi, heterofi lna protutijela, ljudska protumišja protutijela
INTRODUCTION
Interference is caused by interaction with one 
or more steps in the immunoassay procedure and 
the analyte concentration or the antibody binding 
is infl uenced (2). Interference may increase (posi-
tive interference) or decrease (negative interfer-
ence) the measured result and can be analyte-de-
pendent or analyte-independent. 
Analyte-dependent interferences in immu-
noassays are caused by interaction between com-
ponents in the sample with one or more reagent 
antibodies. The common interferences of hemoly-
sis, icterus, lipemia, eﬀ ects of anticoagulants and 
simple storage are independent of the analyte con-
centration.
Endogenous interfering substances can occur 
in both healthy and pathological patient samples. 
Each patient has his own unique sample proper-
ties and interference results from an interaction 
with one or more steps in the immunoassay proce-
dure. The measurable analyte concentration in the 
sample or antibody binding is altered by many 
factors (Table 1) (3).
Exogenous interferences are any interference 
caused by the introduction of external factors or 
conditions. Any external factors, in vivo or in vi-
tro, which are not normally present in native, 
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properly collected and stored samples can intro-
duce interference. For example, hemolysis, lipe-
mia, icterus, blood collection, tube additives, ad-
ministration of radioactive or fl uorescent com-
pounds, drugs, herbal medicines, nutritional 
supplements, sample storage and transport are all 
exogenous interferences that can adversely aﬀ ect 
immunoassays (4). 
A choice of diﬀ erent interference eﬀ ects 
which may appear in immunoassays are schemat-
ically shown in Figure1. Diﬀ erent interference ef-
fect can yield false positive or in some case false 
negative results
One of the most common interference in im-
munoassays is a cross-reaction. Cross-reaction is a 
problem in diagnostic immunoassays where en-
dogenous molecules with a similar structure to 
the measured analyte exist of where metabolites 
of the analyte have common cross-reacting epit-
opes, and where there is administration of struc-
turally similar medications (7).
Pre-analytical factors 
Blood collection tubes are not inert contain-
ers. Silicone oils present in some blood collection 
devices or tubes can physically interfere with anti-
gen-antibody binding. 
For the sample type, according to the NACB 
(National Academy of Clinical Biochemistry) rec-
ommendations of quality requirements in the pre-
analytical phase (9), serum or plasma are usually 
equally appropriate for immunochemistry analy-
sis.
Hemolysis and icterus do not aﬀ ect immu-
noassays as other analytes measured by spectral 
or chemical means. Samples with any sign of he-
molysis are not acceptable for immunoassays of 
relatively labile analytes due to the release of pro-
teolytic enzymes from erythrocytes that degrade 
these analytes (calcitonin, parathyroid hormone, 
gastrin). Lipemia can interfere in some immuno-
assays may produce erroneous results in some as-
says by interfering with antigen binding, even 
when antibodies are linked to a solid support (6).
Stability of the tumor markers are generally 
stable, but serum or plasma should be separated 
from the clot and stored at 4° C (short-term) or 
-30° C (long-term) as soon as possible. 
Carryover due to inadequate washing or fail-
ure to detect a sample clot can result in over- or 
under-estimation of values, but with fully auto-
mated process carryover factor is reduced to mini-
mum.
Hormone binding globulins such as albumin 
(because of its large concentration), sex hormone 
binding globulin (SHBG), thyroid binding globu-
lin (TBG) and cortisol binding globulin (CBG) can 
alter the measurable analyte concentration in the 
Table 1.
NATURE OF INTERFERENCES.
1.  Interferences that alter the measurable analyte concentration 
in the sample
• Hormone binding proteins
• Pre-analytical factors, e.g., anticoagulants, sample storage
• Autoanalyte antibodies
 2.  Interferences that alter antibody binding
• Heterophile antibodies
• Human anti-animal antibodies
• High-dose hook effect
F igure 1. Diﬀ erent interfaces in immunometric immunoassays (5):
Aa  –  assay without any interference;
Ab  –  cross-reactivity of an interfering substance with capture 
antibody, resulting in false negative results
B  –  positive interference:
Ba  –  unspecifi c binding of labelled detector antibody to a not 
blocked solid phase;
Bb  –  “bridge” binding by heterophilic antibodies or HAMA, re-
spectively;
C  –  negative interference:
Ca  –  change or sterical confi rmation after binding or interfering 
protein to Fc fragment of detector antibody
Cb  –  masking of the epitope on analyte surface by a protein of 
the sample
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sample either by removal or blocking of the ana-
lyte (6). 
Autoantibodies have been described that can 
cause interference for a number of analytes in-
cluding thyroid hormones in both free and total 
forms (10), thyroglobulin (11). Positive or negative 
infl uence may occur, depending on whether the 
autoantibody-analyte complex partitions into the 
free or the bound analyte fraction. Interference 
from autoantibodies can occur in both immunoas-
say formats (6).
Antibody interference 
There are two types of endogenous antibod-
ies in patient´s specimen, heterophilic antibodies 
and human anti-animal antibodies. 
Heterophilic antibodies are antibodies pro-
duced against poorly defi ned antigens. They are 
multi-specifi c antibodies of the early immune re-
sponse and generally show low aﬃ  nity and weak 
binding (8). Human anti-animal antibodies (HAAA) 
are high-aﬃ  nity, specifi c polyclonal antibodies 
generated after contact with animal immunoglobu-
lin (12).
The most common anti-animal antibodies are 
human anti-mouse antibodies (HAMA). Mouse 
monoclonal antibodies are applying mostly for a 
therapy and diagnostic purposes. HAMA can in-
terfere with mouse monoclonal antibodies that are 
the main component of the reagent.
Heterophilic antibodies interfere with immu-
noassays and can bind to the conjugate, enzyme, 
or other parts of the detection system in reagent-
limited assays. The same heterophile may react 
diﬀ erently for diﬀ erent antibody combinations 
hence giving rise to a falsely elevated result in one 
assay but a lower result in another assay. Reagent 
manufactures routinely add blocking agent to 
their assay formulations in order to reduce inter-
ference.
High-dose hook eﬀ ect
The hook eﬀ ect is caused by excessively high 
concentrations of analyte simultaneously saturat-
ing both capture and detector antibodies (Figure 2).
In immunoassays with very large analyte 
concentration ranges antigen-antibody reactions 
can go into antigen excess and result in falsely de-
creased results and potential misdiagnosis (6). To 
avoid high/dose hook eﬀ ect the quantity of the re-
agent antibodies must be increased and/or reduce 
the amount of sample required for analysis. De-
sign assay should ensure that the concentrations 
of both capture and detector antibodies are suﬃ  -
ciently high to manage with levels of analytes over 
the entire pathological range.
CONCLUSION
Interference in immunoassays is a serious 
problem which can have important clinical conse-
quences and may lead to unnecessary clinical in-
vestigation as well as inappropriate treatment 
with potentially unfavorable outcome for the pa-
tient. There is no single procedure that can rule 
out all interferences. It is important to recognize 
the potential for interference in immunoassay and 
to put procedures in place to identify them wher-
ever possible. Process need to be in place in order 
to make both laboratories and physicians aware of 
the potential for immunoassay interference, which 
can lead to clinical misinterpretation. In table 2. 
are shown some of the most common interferenc-
es (11–14). 
Most important is a consideration of the clin-
ical picture. If there is any suspicion of discor-
dance between the clinical and the laboratory data 
an att empt should be made to reconcile the diﬀ er-
ence. Constant dialogue is required between phy-
sician and laboratory about unexpected immuno-
assay results. Physicians should be encouraged 
to communicate specifi cally with the laboratory 
Figure 2.The hook eﬀ ect - An excessive amount of analyte over-
whelms the binding capacity of the capture antibody. This re-
sults in an inappropriately low signal that causes erroneous low 
or normal result (“hooked” result) for a patient with an exces-
sively elevated serum analyte concentration (5).
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about discordance between results and clinical 
fi ndings. 
The process should also include on-going 
education, review of patient results in the clinical 
sett ing, protocols for the testing of suspected in-
terference, and notifi cation of interferences both 
to the physician and to the diagnostic manufac-
turer. 
Interference in immunoassays is a serious 
problem which can have important clinical conse-
quences and may lead to unnecessary clinical in-
vestigation as well as inappropriate treatment 
with potentially unfavorable outcome for the pa-
tient. There is no single procedure that can rule 
out all interferences. It is important to recognize 
the potential for interference in immunoassay and 
to put procedures in place to identify them wher-
ever possible. Process need to be in place in order 
to make both laboratories and physicians aware of 
the potential for immunoassay interference, which 
can lead to clinical misinterpretation. 
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gynecologic diseases), other cancer diseases.
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with secretion (saliva, etc.), benign disease (chronic 
hepatitis, cholestasis, gynecologic diseases).
Patients with blood group 
Levis(a) and Levis(b).









Total specifi c 
prostate antigen
tPSA
Hormonal therapy, prostate manipulation and ultrasound 
examination, ejaculation, other cancer disease (breast 
cancer, salivary gland neoplasms). 
Prolonged time to sample 
spin, thermal sample 
manipulation.





Heterophile antibodies, non-specifi c protein binders, Renal 
disease, menopause, cannabis consummation.






AntiTPO, HAMA and auto antibodies
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T4 and free form
fT4
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T3 and free form
fT3
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thyroid binding globulin 
(TBG)
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